Cover
Cover - shares | 3 Months Ended | |
Mar. 31, 2021 | Apr. 23, 2021 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-37565 | |
Entity Registrant Name | NovoCure Limited | |
Entity Incorporation, State or Country Code | Y9 | |
Entity Tax Identification Number | 98-1057807 | |
Entity Address, Address Line One | No. 4 The Forum | |
Entity Address, Address Line Two | Grenville Street | |
Entity Address, City or Town | St. Helier | |
Entity Address, Country | JE | |
Entity Address, Postal Zip Code | JE2 4UF | |
City Area Code | 44 (0) 15 | |
Local Phone Number | 3475 6700 | |
Title of 12(b) Security | Ordinary Shares, no par value | |
Trading Symbol | NVCR | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 103,413,367 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001645113 | |
Current Fiscal Year End Date | --12-31 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 314,547 | $ 234,674 |
Short-term investments | 549,855 | 607,902 |
Restricted cash | 11,430 | 11,499 |
Trade receivables, net | 92,514 | 96,699 |
Receivables and prepaid expenses | 18,922 | 21,245 |
Inventories | 27,968 | 27,422 |
Total current assets | 1,015,236 | 999,441 |
LONG-TERM ASSETS: | ||
Property and equipment, net | 11,733 | 11,395 |
Field equipment, net | 12,132 | 11,230 |
Right-of-use assets | 17,741 | 19,009 |
Other long-term assets | 10,788 | 10,908 |
Total long-term assets | 52,394 | 52,542 |
TOTAL ASSETS | 1,067,630 | 1,051,983 |
CURRENT LIABILITIES: | ||
Trade payables | 52,703 | 53,647 |
Other payables, lease liabilities and accrued expenses | 57,784 | 59,965 |
Total current liabilities | 110,487 | 113,612 |
LONG-TERM LIABILITIES: | ||
Long-term debt, net | 559,584 | 429,905 |
Deferred revenue | 9,577 | 12,139 |
Long-term leases | 12,708 | 14,293 |
Employee benefits | 2,963 | 5,171 |
Other long-term liabilities | 177 | 337 |
Total long-term liabilities | 585,009 | 461,845 |
TOTAL LIABILITIES | 695,496 | 575,457 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS' EQUITY: | ||
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 103,187,460 shares and 102,334,276 shares at March 31, 2021 (unaudited) and December 31, 2020, respectively | 0 | 0 |
Additional paid-in capital | 1,005,785 | 1,111,435 |
Accumulated other comprehensive income (loss) | (1,948) | (3,832) |
Retained earnings (accumulated deficit) | (631,703) | (631,077) |
TOTAL SHAREHOLDERS' EQUITY | 372,134 | 476,526 |
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ 1,067,630 | $ 1,051,983 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares | Mar. 31, 2021 | Dec. 31, 2020 |
Statement of Financial Position [Abstract] | ||
Common stock, shares issued | 103,187,460 | 102,334,276 |
Common stock, shares outstanding | 103,187,460 | 102,334,276 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net revenues | $ 134,695 | $ 101,828 | $ 494,366 |
Cost of revenues | 26,385 | 24,496 | 106,501 |
Gross profit | 108,310 | 77,332 | 387,865 |
Operating costs and expenses: | |||
Research, development and clinical trials | 45,916 | 25,271 | 132,010 |
Sales and marketing | 31,357 | 28,834 | 118,017 |
General and administrative | 31,125 | 26,608 | 107,437 |
Total operating costs and expenses | 108,398 | 80,713 | 357,464 |
Operating income (loss) | (88) | (3,381) | 30,401 |
Financial expenses (income), net | 2,646 | 2,432 | 12,299 |
Income (loss) before income tax | (2,734) | (5,813) | 18,102 |
Income tax | 1,394 | (9,765) | (1,706) |
Net income (loss) | $ (4,128) | $ 3,952 | $ 19,808 |
Basic net income (loss) per ordinary share (in usd per share) | $ (0.04) | $ 0.04 | $ 0.20 |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 102,633,545 | 99,877,567 | 100,930,866 |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.04) | $ 0.04 | $ 0.18 |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 102,633,545 | 108,100,623 | 108,877,648 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Statement of Comprehensive Income [Abstract] | |||
Net income (loss) | $ (4,128) | $ 3,952 | $ 19,808 |
Other comprehensive income (loss), net of tax: | |||
Change in foreign currency translation adjustments | (268) | (200) | (85) |
Pension benefit plan | 2,152 | (662) | (980) |
Total comprehensive income (loss) | $ (2,244) | $ 3,090 | $ 18,743 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands | Total | Cumulative Effect, Period of Adoption, Adjustment | Ordinary shares | Additional paid-in capital | Additional paid-in capitalCumulative Effect, Period of Adoption, Adjustment | Accumulated other comprehensive loss | Retained earnings (accumulated deficit) | Retained earnings (accumulated deficit)Cumulative Effect, Period of Adoption, Adjustment |
Beginning balance at Dec. 31, 2019 | $ 217,790 | $ 871,442 | $ (2,767) | $ (650,885) | ||||
Beginning balance (in shares) at Dec. 31, 2019 | 99,528,435 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Share-based compensation to employees | 16,557 | 16,557 | ||||||
Exercise of options and vested RSUs | 4,511 | 4,511 | ||||||
Exercise of options and vested RSUs (in shares) | 834,538 | |||||||
Other comprehensive income (loss), net of tax benefit | (862) | (862) | ||||||
Net income (loss) | 3,952 | 3,952 | ||||||
Ending balance at Mar. 31, 2020 | 241,948 | 892,510 | (3,629) | (646,933) | ||||
Ending balance (in shares) at Mar. 31, 2020 | 100,362,973 | |||||||
Beginning balance at Dec. 31, 2019 | 217,790 | 871,442 | (2,767) | (650,885) | ||||
Beginning balance (in shares) at Dec. 31, 2019 | 99,528,435 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income (loss) | 19,808 | |||||||
Ending balance at Dec. 31, 2020 | 476,526 | $ (128,972) | 1,111,435 | $ (132,474) | (3,832) | (631,077) | $ 3,502 | |
Ending balance (in shares) at Dec. 31, 2020 | 102,334,276 | |||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Share-based compensation to employees | 18,863 | 18,863 | ||||||
Exercise of options and vested RSUs | 7,961 | 7,961 | ||||||
Exercise of options and vested RSUs (in shares) | 853,184 | |||||||
Other comprehensive income (loss), net of tax benefit | 1,884 | 1,884 | ||||||
Net income (loss) | (4,128) | (4,128) | ||||||
Ending balance at Mar. 31, 2021 | $ 372,134 | $ 1,005,785 | $ (1,948) | $ (631,703) | ||||
Ending balance (in shares) at Mar. 31, 2021 | 103,187,460 |
CONSOLIDATED STATEMENTS OF CH_2
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | ||
Other comprehensive income (loss), tax benefit | $ 0 | $ 0 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Cash flows from operating activities: | |||
Net income (loss) | $ (4,128) | $ 3,952 | $ 19,808 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||
Depreciation and amortization | 2,370 | 1,888 | 9,150 |
Asset write-downs and impairment of field equipment | 176 | 6 | 429 |
Share-based compensation | 18,863 | 16,557 | 75,721 |
Foreign currency remeasurement loss (gain) | 2,157 | (7) | (699) |
Decrease (increase) in accounts receivables | 4,624 | (19,718) | (30,354) |
Amortization of discount (premium) | 603 | (539) | 3,260 |
Decrease (increase) in inventories | (1,296) | 1,147 | (2,935) |
Decrease (increase) in other long-term assets | 1,432 | 1,235 | (1,366) |
Increase (decrease) in accounts payables and accrued expenses | (2,626) | (2,339) | 25,470 |
Increase (decrease) in other long-term liabilities | (4,394) | (225) | 664 |
Net cash provided by (used in) operating activities | 17,780 | 1,957 | 99,148 |
Cash flows from investing activities: | |||
Purchase of property, equipment and field equipment | (3,981) | (3,112) | (14,968) |
Proceeds from maturity of short-term investments | 608,000 | 0 | 150,000 |
Purchase of short-term investments | (549,848) | 0 | (607,879) |
Net cash provided by (used in) investing activities | 54,171 | (3,112) | (472,847) |
Cash flows from financing activities: | |||
Proceeds from issuance of shares, net | 0 | 0 | 3,370 |
Proceeds from long term debt, net | 0 | 0 | 558,439 |
Repayment of long-term loan | (6) | (8) | (150,028) |
Exercise of options and warrants | 7,961 | 4,511 | 28,428 |
Net cash provided by (used in) financing activities | 7,955 | 4,503 | 440,209 |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | (102) | (59) | 247 |
Increase (decrease) in cash, cash equivalents and restricted cash | 79,804 | 3,289 | 66,757 |
Cash, cash equivalents and restricted cash at the beginning of the period | 246,173 | 179,416 | 179,416 |
Cash, cash equivalents and restricted cash at the end of the period | 325,977 | 182,705 | 246,173 |
Cash paid during the period for: | |||
Income taxes paid (refunded), net | (2,405) | 2,209 | (3,261) |
Interest paid | 1 | 3,415 | 8,686 |
Non-cash activities: | |||
Right-of-use assets obtained in exchange for lease liabilities | $ 284 | $ 783 | $ 5,617 |
Organization and Basis of Prese
Organization and Basis of Presentation | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Basis of Presentation | ORGANIZATION AND BASIS OF PRESENTATION Organization . NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") delivery systems, including Optune and Optune Lua (collectively, our "Products"), for the treatment of solid tumor cancers. The Company currently markets Optune in the United States ("U.S."), Austria, Germany, Israel, Japan, Sweden and Switzerland. The Company currently markets Optune Lua in the U.S. The Company also has a License and Collaboration Agreement (the "Zai Agreement") with Zai Lab (Shanghai) Co., Ltd. ("Zai") to market Optune in Greater China. Financial statement preparation . The accompanying unaudited consolidated financial statements include the accounts of the Company and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation for the periods presented. The preparation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the "2020 10-K') filed with the Securities and Exchange Commission on February 25, 2021. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2020 10-K are applied consistently in these unaudited interim consolidated financial statements, except as noted below: Recently Adopted Accounting Pronouncements. In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted ASU 2020-06, effective January 1, 2021 on a modified retrospective basis. The impact of the Company’s adoption of ASU 2020-06 on the balance sheet as of January 1, 2021 was an increase in long term debt, net of $128,972, a decrease in additional paid-in capital of $132,474, and a decrease in accumulated deficit of $3,502. Interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. For additional information see Note 5 of these unaudited consolidated financial statements. In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance. ASU 2019-12 is effective for the Company as of January 1, 2021 and the adoption of this standard did not have a material impact on the Company's consolidated financial statements. |
Cash, Cash Equivalents and Shor
Cash, Cash Equivalents and Short-Term Investments | 3 Months Ended |
Mar. 31, 2021 | |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | |
Cash, Cash Equivalents and Short-Term Investments | CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. As of March 31, 2021 and December 31, 2020, the Company’s cash and cash equivalents were composed of: March 31, December 31, Unaudited Audited Cash $ 31,849 $ 20,339 Money market funds 282,698 214,335 Total cash and cash equivalents $ 314,547 $ 234,674 The Company also invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments. As of March 31, 2021 and December 31, 2020, the Company’s short-term investments were: March 31, December 31, Unaudited Audited Short-term investments $ 549,855 $ 607,902 Quoted market prices were applied to determine the fair value of cash equivalents and short-term investments, therefore they were categorized as Level 1 in accordance with Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures.” The estimated fair value of the Company’s short-term investments as of March 31, 2021 and December 31, 2020 was $549,890 and $607,905, respectively. |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Inventories | INVENTORIES Inventories are stated at the lower of cost or net realizable value. The weighted average methodology is applied to determine cost. As of March 31, 2021 and December 31, 2020, the Company’s inventories were composed of: March 31, December 31, Unaudited Audited Raw materials $ 3,376 $ 5,175 Work in progress 9,342 4,896 Finished products 15,250 17,351 Total $ 27,968 $ 27,422 |
Commitments and Contingent Liab
Commitments and Contingent Liabilities | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingent Liabilities | COMMITMENTS AND CONTINGENT LIABILITIES Operating Leases. The facilities of the Company are leased under various operating lease agreements for periods, including options for extensions, ending no later than 2030. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2024. Pledged deposits and bank guarantees. As of March 31, 2021 and December 31, 2020, the Company pledged bank deposits of $1,409 and $1,438, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained bank guarantees for the fulfillment of the Company’s lease and other contractual commitments of $1,649 and $1,687, respectively . Senior secured revolving credit facility. On November 6, 2020, the Company entered into a new three-year $150,000 senior secured revolving credit facility with a syndicate of relationship banks. For additional information, see Note 12(c) to the Consolidated Financial Statements in the 2020 10-K. As of March 31, 2021, the Company had no outstanding balance borrowed under the facility. |
Convertible Note
Convertible Note | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Convertible Note | CONVERTIBLE NOTE On November 5, 2020, the Company issued $575,000 aggregate principal amount of 0% Convertible Senior Notes due 2025 (the “Notes”). The Notes are senior unsecured obligations of the Company. The Notes do not bear regular interest, and the principal amount of the Notes will not accrete. Special interest, if any, payable in accordance with the terms of the Notes will be payable in cash semi-annually in arrears on May 1 and November 1 of each year, beginning on May 1, 2021. The Notes mature on November 1, 2025, unless earlier repurchased, redeemed or converted. For additional information, see Note 10(a) to the Consolidated Financial Statements in the 2020 10-K. In January 2021, the Company irrevocably elected to settle all conversions of Notes by a combination of cash and the Company's ordinary shares and that the cash portion per $1,000 principal amount of Notes for all conversion settlements shall be $1,000. Accordingly, from and after the date of the election, upon conversion of any Notes, holders of Notes will receive, with respect to each $1,000 principal amount of Notes converted, cash in an amount up to $1,000 and the balance of the conversion value, if any, in ordinary shares (the "Conversion Shares"). The net carrying amount of the liability and equity components of the Notes as of March 31, 2021 and December 31, 2020 are as follows: March 31, December 31, Unaudited Audited Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized discount — (132,797) Unamortized issuance costs (15,416) (12,298) Net carrying amount of liability component (1) $ 559,584 $ 429,905 Equity component, net: Conversion feature $ — $ 136,402 Issuance costs — (3,928) Net carrying amount of equity component $ — $ 132,474 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the Net carrying amount of liability component of the Notes as of March 31, 2021 and December 31, 2020 were $477,841 and $450,437, respectively. Finance expense related to the Notes was as follows: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Amortization of debt discount $ — $ — $ 3,605 Amortization of debt issuance costs 709 — 333 Total finance expense recognized $ 709 $ — $ 3,938 |
Share Option Plans and ESPP
Share Option Plans and ESPP | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] | |
Share Option Plans and ESPP | SHARE OPTION PLANS AND ESPP In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). Under the 2015 Plan, the Company can issue various types of equity compensation awards such as share options, restricted shares, performance shares, restricted share units (“RSUs”), performance-based share units (“PSUs”), long-term cash awards and other share-based awards. Options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are canceled or forfeited before expiration become available for future grants. RSUs granted under the 2015 Plan generally vest over a three year period. PSUs granted under the 2015 Plan generally vest between a three A summary of the status of the Company’s option plans as of March 31, 2021 and changes during the period then ended is presented below: Three months ended March 31, 2021 Unaudited Number Weighted Outstanding at beginning of year 9,220,326 $ 26.21 Granted 375,689 153.09 Exercised (404,591) 19.36 Forfeited and canceled (20,911) 62.86 Outstanding as of March 31, 2021 9,170,513 $ 31.63 Exercisable options 5,344,848 $ 18.59 For the three months ended March 31, 2021, options to purchase 404,591 ordinary shares were exercised, resulting in the issuance of 404,591 ordinary shares. A summary of the status of the Company’s RSUs and PSUs as of March 31, 2021 and changes during the period then ended is presented below. Three months ended March 31, 2021 Unaudited Number Weighted Unvested at beginning of year 4,466,151 $ 54.06 Granted 538,908 139.43 Vested (448,593) 48.38 Forfeited and cancelled (12,262) 75.05 Unvested as of March 31, 2021 (1) 4,544,204 64.69 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2021, in accordance with ASC 718 as follows: March 31, 2021 Number of Fair value at grant date per PSU Total fair value at gtant date 2,703,852 $ 48.16 $ 130,218 216,226 69.37 15,000 35,424 84.68 3,000 94,813 $ 114.26 10,833 3,050,315 $ 159,050 These PSUs will be expensed over the performance period when the vesting conditions become probable in accordance with ASC 718. In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP are construed in a manner consistent with the requirements of such section. As of March 31, 2021, 5,006,367 ordinary shares were available to be purchased by eligible employees under the ESPP. The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Stock Option Plans Expected term (years) 5.86-6.00 6.25 5.50-6.00 Expected volatility 60 % 54 % 54%-56% Risk-free interest rate 0.85%-0.88% 0.86 % 0.30%-0.86% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 55 % 47 % 47%-66% Risk-free interest rate 0.09 % 1.57 % 0.17%-1.57% Dividend yield 0.00 % 0.00 % 0.00 % The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2021 and 2020 and the year ended December 31, 2020 was: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Cost of revenues $ 733 $ 590 $ 2,221 Research, development and clinical trials 5,124 3,394 18,125 Sales and marketing 4,471 3,616 17,672 General and administrative 8,535 8,957 37,703 Total share-based compensation expense $ 18,863 $ 16,557 $ 75,721 |
Basic and Diluted Net Income (L
Basic and Diluted Net Income (Loss) Per Ordinary Share | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Basic and Diluted Net Income (Loss) Per Ordinary Share | Basic and diluted net income (loss) per ordinary shareBasic net income (loss) per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted net income per share is computed based on the weighted average number of ordinary shares outstanding during the period, plus potential dilutive shares (deriving from options, RSUs, PSUs, convertible notes and the ESPP) considered outstanding during the period, in accordance with ASC 260-10, as determined under the if-converted method. The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Net income (loss) attributable to ordinary shares as reported $ (4,128) $ 3,952 $ 19,808 Net income (loss) used in computing basic net income (loss) per share $ (4,128) $ 3,952 $ 19,808 Adjustment needed in calculating diluted net income (loss) per share — — — Net income (loss) used in computing diluted net income (loss) per share $ (4,128) $ 3,952 $ 19,808 Weighted average number of ordinary shares used in computing basic net income (loss) per share 102,633,545 99,877,567 100,930,866 Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: Options — 7,113,992 6,967,554 Restricted share units — 1,094,385 945,612 ESPP — 14,679 33,616 Weighted average number of ordinary shares used in computing diluted net income (loss) per share 102,633,545 108,100,623 108,877,648 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 9,734,269 352,291 1,307,762 Basic net income (loss) per ordinary share $ (0.04) $ 0.04 $ 0.20 Diluted net income (loss) per ordinary share $ (0.04) $ 0.04 $ 0.18 |
Supplemental Information
Supplemental Information | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Supplemental Information | SUPPLEMENTAL INFORMATION The Company operates in a single reportable segment. The following table presents long-lived assets by location: March 31, December 31, Unaudited Audited United States $ 12,418 $ 11,868 Israel 4,552 4,370 Switzerland 4,048 2,849 Japan 1,042 1,230 Germany 1,084 1,075 Others 721 1,233 Total $ 23,865 $ 22,625 The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited United States $ 85,908 $ 69,259 $ 340,782 EMEA: Germany 26,364 21,802 93,264 Other EMEA 8,619 2,674 18,654 Japan 8,278 6,451 29,076 Greater China (1) 5,526 1,642 12,590 Total net revenues $ 134,695 $ 101,828 $ 494,366 (1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2020 10-K. |
Organization and Basis of Pre_2
Organization and Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Recently Adopted Accounting Pronouncements | Recently Adopted Accounting Pronouncements. In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. Among other changes, ASU 2020-06 removes from GAAP the liability and equity separation model for convertible instruments with a cash conversion feature, and as a result, after adoption, entities will no longer separately present in equity an embedded conversion feature for such debt. Similarly, the embedded conversion feature will no longer be amortized into income as interest expense over the life of the instrument. Instead, entities will account for a convertible debt instrument wholly as debt unless (1) a convertible instrument contains features that require bifurcation as a derivative under ASC Topic 815, Derivatives and Hedging, or (2) a convertible debt instrument was issued at a substantial premium. Additionally, ASU 2020-06 requires the application of the if-converted method to calculate the impact of convertible instruments on diluted earnings per share (EPS), which is consistent with the Company’s accounting treatment under the current standard. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted for fiscal years beginning after December 15, 2020, and can be adopted on either a fully retrospective or modified retrospective basis. The Company early adopted ASU 2020-06, effective January 1, 2021 on a modified retrospective basis. The impact of the Company’s adoption of ASU 2020-06 on the balance sheet as of January 1, 2021 was an increase in long term debt, net of $128,972, a decrease in additional paid-in capital of $132,474, and a decrease in accumulated deficit of $3,502. Interest expense recognized in future periods will be reduced as a result of accounting for the convertible debt instrument as a single liability measured at its amortized cost. For additional information see Note 5 of these unaudited consolidated financial statements. In December 2019, the FASB issued Accounting Standard Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (ASU 2019-12), which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance. ASU 2019-12 is effective for the Company as of January 1, 2021 and the adoption of this standard did not have a material impact on the Company's consolidated financial statements. |
Cash, Cash Equivalents and Sh_2
Cash, Cash Equivalents and Short-Term Investments (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | |
Summary of Cash and Cash Equivalents | As of March 31, 2021 and December 31, 2020, the Company’s cash and cash equivalents were composed of: March 31, December 31, Unaudited Audited Cash $ 31,849 $ 20,339 Money market funds 282,698 214,335 Total cash and cash equivalents $ 314,547 $ 234,674 |
Summary of Amortized Cost and Recorded Basis of T-bills in Short-Term Investments | As of March 31, 2021 and December 31, 2020, the Company’s short-term investments were: March 31, December 31, Unaudited Audited Short-term investments $ 549,855 $ 607,902 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories | As of March 31, 2021 and December 31, 2020, the Company’s inventories were composed of: March 31, December 31, Unaudited Audited Raw materials $ 3,376 $ 5,175 Work in progress 9,342 4,896 Finished products 15,250 17,351 Total $ 27,968 $ 27,422 |
Convertible Note (Tables)
Convertible Note (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Debt Disclosure [Abstract] | |
Summary of the Convertible Notes | The net carrying amount of the liability and equity components of the Notes as of March 31, 2021 and December 31, 2020 are as follows: March 31, December 31, Unaudited Audited Liability component, net: Principal amount $ 575,000 $ 575,000 Unamortized discount — (132,797) Unamortized issuance costs (15,416) (12,298) Net carrying amount of liability component (1) $ 559,584 $ 429,905 Equity component, net: Conversion feature $ — $ 136,402 Issuance costs — (3,928) Net carrying amount of equity component $ — $ 132,474 (1) An effective interest rate determines the fair value of the Notes, therefore they are categorized as Level 3 in accordance with ASC 820, "Fair Value Measurements and Disclosures." The estimated fair value of the Net carrying amount of liability component of the Notes as of March 31, 2021 and December 31, 2020 were $477,841 and $450,437, respectively. Finance expense related to the Notes was as follows: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Amortization of debt discount $ — $ — $ 3,605 Amortization of debt issuance costs 709 — 333 Total finance expense recognized $ 709 $ — $ 3,938 |
Share Option Plans and ESPP (Ta
Share Option Plans and ESPP (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract] | |
Schedule of Stock Option Plans | A summary of the status of the Company’s option plans as of March 31, 2021 and changes during the period then ended is presented below: Three months ended March 31, 2021 Unaudited Number Weighted Outstanding at beginning of year 9,220,326 $ 26.21 Granted 375,689 153.09 Exercised (404,591) 19.36 Forfeited and canceled (20,911) 62.86 Outstanding as of March 31, 2021 9,170,513 $ 31.63 Exercisable options 5,344,848 $ 18.59 |
Schedule of RSUs and PSUs | A summary of the status of the Company’s RSUs and PSUs as of March 31, 2021 and changes during the period then ended is presented below. Three months ended March 31, 2021 Unaudited Number Weighted Unvested at beginning of year 4,466,151 $ 54.06 Granted 538,908 139.43 Vested (448,593) 48.38 Forfeited and cancelled (12,262) 75.05 Unvested as of March 31, 2021 (1) 4,544,204 64.69 (1) Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of performance milestones which are not probable, as of March 31, 2021, in accordance with ASC 718 as follows: March 31, 2021 Number of Fair value at grant date per PSU Total fair value at gtant date 2,703,852 $ 48.16 $ 130,218 216,226 69.37 15,000 35,424 84.68 3,000 94,813 $ 114.26 10,833 3,050,315 $ 159,050 |
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model | The fair value of share-based awards was estimated using the Black-Scholes model for all equity grants. For market condition awards, the Company also applied the Monte-Carlo simulation model. We assessed fair value using the following underlying assumptions: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Stock Option Plans Expected term (years) 5.86-6.00 6.25 5.50-6.00 Expected volatility 60 % 54 % 54%-56% Risk-free interest rate 0.85%-0.88% 0.86 % 0.30%-0.86% Dividend yield 0.00 % 0.00 % 0.00 % ESPP Expected term (years) 0.50 0.50 0.50 Expected volatility 55 % 47 % 47%-66% Risk-free interest rate 0.09 % 1.57 % 0.17%-1.57% Dividend yield 0.00 % 0.00 % 0.00 % |
Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards | The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three months ended March 31, 2021 and 2020 and the year ended December 31, 2020 was: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Cost of revenues $ 733 $ 590 $ 2,221 Research, development and clinical trials 5,124 3,394 18,125 Sales and marketing 4,471 3,616 17,672 General and administrative 8,535 8,957 37,703 Total share-based compensation expense $ 18,863 $ 16,557 $ 75,721 |
Basic and Diluted Net Income _2
Basic and Diluted Net Income (Loss) Per Ordinary Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Net Loss Per Ordinary Share | The following table sets forth the computation of the Company’s basic and diluted net income (loss) per ordinary share: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited Net income (loss) attributable to ordinary shares as reported $ (4,128) $ 3,952 $ 19,808 Net income (loss) used in computing basic net income (loss) per share $ (4,128) $ 3,952 $ 19,808 Adjustment needed in calculating diluted net income (loss) per share — — — Net income (loss) used in computing diluted net income (loss) per share $ (4,128) $ 3,952 $ 19,808 Weighted average number of ordinary shares used in computing basic net income (loss) per share 102,633,545 99,877,567 100,930,866 Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: Options — 7,113,992 6,967,554 Restricted share units — 1,094,385 945,612 ESPP — 14,679 33,616 Weighted average number of ordinary shares used in computing diluted net income (loss) per share 102,633,545 108,100,623 108,877,648 Weighted anti-dilutive shares outstanding which were not included in the diluted calculation 9,734,269 352,291 1,307,762 Basic net income (loss) per ordinary share $ (0.04) $ 0.04 $ 0.20 Diluted net income (loss) per ordinary share $ (0.04) $ 0.04 $ 0.18 |
Supplemental Information (Table
Supplemental Information (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Segment Reporting [Abstract] | |
Schedule of Long-Lived Assets by Location | The following table presents long-lived assets by location: March 31, December 31, Unaudited Audited United States $ 12,418 $ 11,868 Israel 4,552 4,370 Switzerland 4,048 2,849 Japan 1,042 1,230 Germany 1,084 1,075 Others 721 1,233 Total $ 23,865 $ 22,625 |
Schedule of Revenues by Geographic Region | The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows: Three months ended March 31, Year ended December 31, 2021 2020 Unaudited Audited United States $ 85,908 $ 69,259 $ 340,782 EMEA: Germany 26,364 21,802 93,264 Other EMEA 8,619 2,674 18,654 Japan 8,278 6,451 29,076 Greater China (1) 5,526 1,642 12,590 Total net revenues $ 134,695 $ 101,828 $ 494,366 (1) For additional information, see Note 12 to the Consolidated Financial Statements in the 2020 10-K. |
Organization and Basis of Pre_3
Organization and Basis of Presentation (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 |
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | $ 372,134 | $ 476,526 | $ 241,948 | $ 217,790 |
Additional paid-in capital | ||||
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | 1,005,785 | 1,111,435 | 892,510 | 871,442 |
Retained earnings (accumulated deficit) | ||||
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | $ (631,703) | (631,077) | $ (646,933) | $ (650,885) |
Cumulative Effect, Period of Adoption, Adjustment | ||||
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | (128,972) | |||
Cumulative Effect, Period of Adoption, Adjustment | Additional paid-in capital | ||||
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | (132,474) | |||
Cumulative Effect, Period of Adoption, Adjustment | Retained earnings (accumulated deficit) | ||||
New Accounting Pronouncement, Early Adoption [Line Items] | ||||
Stockholders' equity | $ 3,502 |
Cash, Cash Equivalents and Sh_3
Cash, Cash Equivalents and Short-Term Investments - Summary of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | ||
Cash | $ 31,849 | $ 20,339 |
Money market funds | 282,698 | 214,335 |
Total cash and cash equivalents | $ 314,547 | $ 234,674 |
Cash, Cash Equivalents and Sh_4
Cash, Cash Equivalents and Short-Term Investments - Summary of Amortized Cost And Recorded Basis of T-bills in Short Term Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | ||
Short-term investments | $ 549,855 | $ 607,902 |
Cash, Cash Equivalents and Sh_5
Cash, Cash Equivalents and Short-Term Investments - Additional Information (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Cash, Cash Equivalents, and Short-term Investments [Abstract] | ||
Estimated fair value of short-term investments | $ 549,890 | $ 607,905 |
Inventories (Details)
Inventories (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Inventory Disclosure [Abstract] | ||
Raw materials | $ 3,376 | $ 5,175 |
Work in progress | 9,342 | 4,896 |
Finished products | 15,250 | 17,351 |
Total | $ 27,968 | $ 27,422 |
Commitments and Contingent Li_2
Commitments and Contingent Liabilities (Details) - USD ($) | Nov. 06, 2020 | Mar. 31, 2021 | Dec. 31, 2020 |
Commitments and Contingencies Disclosure [Abstract] | |||
Pledged bank deposits | $ 1,409,000 | $ 1,438,000 | |
Operating lease and other contractual commitments | $ 1,649,000 | $ 1,687,000 | |
Revolving Credit Facility | |||
Line of Credit Facility [Line Items] | |||
Contractual term | 3 years | ||
Maximum borrowing capacity | $ 150,000,000 |
Convertible Note - Additional I
Convertible Note - Additional Information (Details) - Convertible Debt - the “Notes” - USD ($) | 1 Months Ended | |
Jan. 31, 2021 | Nov. 05, 2020 | |
Debt Instrument [Line Items] | ||
Aggregate principal amount | $ 575,000,000 | |
Stated interest rate | 0.00% | |
Cash portion per $1,000 principal amount of Notes converted | $ 1,000,000 |
Convertible Note - Liability an
Convertible Note - Liability and Equity Components of the Convertible Notes (Details) - Convertible Debt - the “Notes” - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Debt Instrument [Line Items] | ||
Principal amount | $ 575,000 | $ 575,000 |
Unamortized discount | 0 | (132,797) |
Unamortized issuance costs | (15,416) | (12,298) |
Net carrying amount of liability component | 559,584 | 429,905 |
Conversion feature | 0 | 136,402 |
Issuance costs | 0 | (3,928) |
Net carrying amount of equity component | 0 | 132,474 |
Estimated fair value | $ 477,841 | $ 450,437 |
Convertible Note - Finance Expe
Convertible Note - Finance Expense Related to the Convertible Notes (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Debt Instrument [Line Items] | |||
Amortization of debt discount | $ 603 | $ (539) | $ 3,260 |
the “Notes” | Convertible Debt | |||
Debt Instrument [Line Items] | |||
Amortization of debt discount | 0 | 0 | 3,605 |
Amortization of debt issuance costs | 709 | 0 | 333 |
Total finance expense recognized | $ 709 | $ 0 | $ 3,938 |
Share Option Plans and ESPP - A
Share Option Plans and ESPP - Additional Information (Details) | 3 Months Ended |
Mar. 31, 2021shares | |
Share Capital [Line Items] | |
Options exercised (in shares) | 404,591 |
ESPP | |
Share Capital [Line Items] | |
Ordinary shares available for grants (in shares) | 5,006,367 |
Shares issued under plan (in shares) | 404,591 |
2015 Plan | |
Share Capital [Line Items] | |
Ordinary shares available for grants (in shares) | 14,450,270 |
2015 Plan | Options | |
Share Capital [Line Items] | |
Stock awards granted, vesting period (years) | 4 years |
Stock awards granted, expiration period (years) | 10 years |
2015 Plan | Restricted share units | |
Share Capital [Line Items] | |
Stock awards granted, vesting period (years) | 3 years |
2015 Plan | PSUs | Minimum | |
Share Capital [Line Items] | |
Stock awards granted, vesting period (years) | 3 years |
2015 Plan | PSUs | Maximum | |
Share Capital [Line Items] | |
Stock awards granted, vesting period (years) | 6 years |
Share Option Plans and ESPP - S
Share Option Plans and ESPP - Schedule of Stock Option Plan (Details) | 3 Months Ended |
Mar. 31, 2021$ / sharesshares | |
Number of options | |
Number of options, beginning outstanding (in shares) | shares | 9,220,326 |
Number of options, granted (in shares) | shares | 375,689 |
Number of options, exercised (in shares) | shares | (404,591) |
Number of options, forfeited and canceled (in shares) | shares | (20,911) |
Number of options, ending outstanding (in shares) | shares | 9,170,513 |
Number of options, exercisable options (in shares) | shares | 5,344,848 |
Weighted average exercise price | |
Weighted average exercise price, beginning outstanding (in usd per share) | $ / shares | $ 26.21 |
Weighted average exercise price, granted (in usd per share) | $ / shares | 153.09 |
Weighted average exercise price, exercised (in usd per share) | $ / shares | 19.36 |
Weighted average exercise price, forfeited and canceled (in usd per share) | $ / shares | 62.86 |
Weighted average exercise price, ending outstanding (in usd per share) | $ / shares | 31.63 |
Weighted average exercise price, exercisable options (in usd per share) | $ / shares | $ 18.59 |
Share Capital - Schedule of RSU
Share Capital - Schedule of RSUs and PSUs (Details) $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2021USD ($)$ / sharesshares | |
RSUs/PSUs | |
Number of RSU/PSUs | |
Unvested at beginning of year (in shares) | 4,466,151 |
Granted (in shares) | 538,908 |
Vested (in shares) | (448,593) |
Forfeited and cancelled (in shares) | (12,262) |
Unvested at ending of year (in shares) | 4,544,204 |
Weighted average grant date fair value | |
Unvested at beginning of year (in usd per share) | $ / shares | $ 54.06 |
Granted (in usd per share) | $ / shares | 139.43 |
Vested (in usd per share) | $ / shares | 48.38 |
Forfeited and cancelled (in usd per share) | $ / shares | 75.05 |
Unvested at ending of year (in usd per share) | $ / shares | $ 64.69 |
PSUs | |
Weighted average grant date fair value | |
Number of PSUs (in shares) | 3,050,315 |
Total fair value at grant date | $ | $ 159,050 |
PSUs | Award One | |
Weighted average grant date fair value | |
Number of PSUs (in shares) | 2,703,852 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 48.16 |
Total fair value at grant date | $ | $ 130,218 |
PSUs | Award Two | |
Weighted average grant date fair value | |
Number of PSUs (in shares) | 216,226 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 69.37 |
Total fair value at grant date | $ | $ 15,000 |
PSUs | Award Three | |
Weighted average grant date fair value | |
Number of PSUs (in shares) | 35,424 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 84.68 |
Total fair value at grant date | $ | $ 3,000 |
PSUs | Award Four | |
Weighted average grant date fair value | |
Number of PSUs (in shares) | 94,813 |
Fair value at grant date per PSU (in usd per share) | $ / shares | $ 114.26 |
Total fair value at grant date | $ | $ 10,833 |
Share Option Plans and ESPP -_2
Share Option Plans and ESPP - Schedule of Fair Value Assumptions Used Only for Equity Based Awards Estimated Using Black-Scholes Option Pricing Model (Details) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
ESPP | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 6 months | 6 months | 6 months |
Expected volatility | 55.00% | 47.00% | |
Expected volatility, minimum | 47.00% | ||
Expected volatility, maximum | 66.00% | ||
Risk-free interest rate | 0.09% | 1.57% | |
Risk-free interest rate, minimum | 0.17% | ||
Risk-free interest rate, maximum | 1.57% | ||
Dividend yield | 0.00% | 0.00% | 0.00% |
Stock Option Plans | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 6 years 3 months | ||
Expected volatility | 60.00% | 54.00% | |
Expected volatility, minimum | 54.00% | ||
Expected volatility, maximum | 56.00% | ||
Risk-free interest rate | 0.86% | ||
Risk-free interest rate, minimum | 0.85% | 0.30% | |
Risk-free interest rate, maximum | 0.88% | 0.86% | |
Dividend yield | 0.00% | 0.00% | 0.00% |
Stock Option Plans | Minimum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 5 years 10 months 9 days | 5 years 6 months | |
Stock Option Plans | Maximum | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Expected term (years) | 6 years | 6 years |
Share Option Plans and ESPP -_3
Share Option Plans and ESPP - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 18,863 | $ 16,557 | $ 75,721 |
Cost of revenues | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 733 | 590 | 2,221 |
Research, development and clinical trials | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 5,124 | 3,394 | 18,125 |
Sales and marketing | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | 4,471 | 3,616 | 17,672 |
General and administrative | |||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | |||
Total share-based compensation expense | $ 8,535 | $ 8,957 | $ 37,703 |
Basic and Diluted Net Income _3
Basic and Diluted Net Income (Loss) Per Ordinary Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] | |||
Net income (loss) | $ (4,128) | $ 3,952 | $ 19,808 |
Net income (loss) used in computing basic net income (loss) per share | (4,128) | 3,952 | 19,808 |
Adjustment needed in calculating diluted net income (loss) per share | 0 | 0 | 0 |
Net income (loss) used in computing diluted net income (loss) per share | $ (4,128) | $ 3,952 | $ 19,808 |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 102,633,545 | 99,877,567 | 100,930,866 |
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 102,633,545 | 108,100,623 | 108,877,648 |
Weighted anti-dilutive shares outstanding which were not included in the diluted calculation (in shares) | 9,734,269 | 352,291 | 1,307,762 |
Basic net income (loss) per ordinary share (in usd per share) | $ (0.04) | $ 0.04 | $ 0.20 |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.04) | $ 0.04 | $ 0.18 |
Options | |||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||
Share-based payment arrangements (in shares) | 0 | 7,113,992 | 6,967,554 |
Restricted share units | |||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||
Share-based payment arrangements (in shares) | 0 | 1,094,385 | 945,612 |
ESPP | |||
Potentially dilutive shares that were excluded from the computation of basic net income (loss) per share: | |||
Share-based payment arrangements (in shares) | 0 | 14,679 | 33,616 |
Supplemental Information - Sche
Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands | Mar. 31, 2021 | Dec. 31, 2020 |
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | $ 23,865 | $ 22,625 |
United States | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | 12,418 | 11,868 |
Israel | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | 4,552 | 4,370 |
Switzerland | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | 4,048 | 2,849 |
Japan | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | 1,042 | 1,230 |
Germany | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | 1,084 | 1,075 |
Others | ||
Revenues from External Customers and Long-Lived Assets [Line Items] | ||
Long-term assets | $ 721 | $ 1,233 |
Supplemental Information - Sc_2
Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | $ 134,695 | $ 101,828 | $ 494,366 |
United States | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | 85,908 | 69,259 | 340,782 |
Germany | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | 26,364 | 21,802 | 93,264 |
Other EMEA | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | 8,619 | 2,674 | 18,654 |
Japan | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | 8,278 | 6,451 | 29,076 |
Greater China | |||
Revenues from External Customers and Long-Lived Assets [Line Items] | |||
Net revenues | $ 5,526 | $ 1,642 | $ 12,590 |